EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C32H40N4O5S |
| Net Charge | 0 |
| Average Mass | 592.762 |
| Monoisotopic Mass | 592.27194 |
| SMILES | CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1 |
| InChI | InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35) |
| InChIKey | WRFHGDPIDHPWIQ-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | angiotensin receptor antagonist A hormone antagonist that blocks angiotensin receptors. endothelin A receptor antagonist A endothelin receptor antagonist is a drug which selectively blocks endothelin A receptors. |
| Applications: | nephroprotective agent Any protective agent that is able to prevent damage to the kidney. angiotensin receptor antagonist A hormone antagonist that blocks angiotensin receptors. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. endothelin A receptor antagonist A endothelin receptor antagonist is a drug which selectively blocks endothelin A receptors. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| sparsentan (CHEBI:229526) has role angiotensin receptor antagonist (CHEBI:61016) |
| sparsentan (CHEBI:229526) has role antihypertensive agent (CHEBI:35674) |
| sparsentan (CHEBI:229526) has role endothelin A receptor antagonist (CHEBI:51452) |
| sparsentan (CHEBI:229526) has role nephroprotective agent (CHEBI:76595) |
| sparsentan (CHEBI:229526) is a azaspiro compound (CHEBI:35624) |
| sparsentan (CHEBI:229526) is a benzyl ether (CHEBI:59859) |
| sparsentan (CHEBI:229526) is a biphenyls (CHEBI:22888) |
| sparsentan (CHEBI:229526) is a isoxazoles (CHEBI:55373) |
| sparsentan (CHEBI:229526) is a sulfonamide (CHEBI:35358) |
| IUPAC Name |
|---|
| 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)[biphenyl]-2-sulfonamide |
| INNs | Source |
|---|---|
| esparsentán | WHO MedNet |
| sparsentan | WHO MedNet |
| sparsentan | WHO MedNet |
| sparsentanum | WHO MedNet |
| Synonyms | Source |
|---|---|
| 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide | ChEBI |
| PS 433540 | ChEBI |
| PS-433540 | DrugBank |
| PS433540 | DrugBank |
| RE-021 | DrugBank |
| Brand Name | Source |
|---|---|
| Filspari | KEGG DRUG |
| Manual Xrefs | Databases |
|---|---|
| D11776 | KEGG DRUG |
| DB12548 | DrugBank |
| Sparsentan | Wikipedia |
| Citations |
|---|